Trial Profile
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ASPIRE
- 31 Oct 2018 Results assessing levels of residual viremia by an ultrasensitive viral load assay to determine whether dolutegravir and lamivudine presented at the 14th International Congress on Drug Therapy and HIV Infection.
- 27 Jul 2018 Results assessing genital HIV-1 shedding with Dolutegravir plus Lamivudine dual therapy in patients from ASPIRE and ACTG-A5353 studies (n=41) presented at the 22nd International AIDS Conference
- 26 Dec 2017 Primary endpoint has been met. (Virologic failure rate) as per results published in the Clinical Infectious Diseases